Patents by Inventor Pascal Mettens

Pascal Mettens has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions and methods
    Patent number: 10286053
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: September 15, 2016
    Date of Patent: May 14, 2019
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • Compositions and methods
    Patent number: 9795663
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: June 28, 2013
    Date of Patent: October 24, 2017
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • Compositions and methods
    Patent number: 9750794
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: March 11, 2016
    Date of Patent: September 5, 2017
    Assignees: GLAXOSMITHKLINE BIOLOGICALS SA, GLAXO GROUP LIMITED
    Inventors: James Brown, Pascal Mettens, Dennis Murphy
  • Compositions and methods
    Patent number: 9480735
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; of (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: May 21, 2014
    Date of Patent: November 1, 2016
    Assignees: Glaxo Group Limited, GlaxoSmithKline Biologicals, SA
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • Compositions and methods
    Patent number: 9315556
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: April 19, 2016
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: James Brown, Pascal Mettens, Dennis Murphy
  • Modified antigens
    Patent number: 9200044
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: December 1, 2015
    Assignee: GlaxoSmithKline Biologicals, S.A.
    Inventors: Normand Blais, Anne-Marie Gelinas, James Brown, Dennis Murphy, Pascal Mettens
  • Modified tuberculosis antigens
    Patent number: 8932600
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Grant
    Filed: January 27, 2011
    Date of Patent: January 13, 2015
    Assignees: GlaxoSmithKline Biologicals S.A., Glaxo Group Limited
    Inventors: Normand Blais, James Brown, Anne-Marie Gelinas, Pascal Mettens, Dennis Murphy
  • NOVEL COMPOSITIONS AND METHODS
    Publication number: 20140178423
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Application
    Filed: June 28, 2013
    Publication date: June 26, 2014
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • VACCINES AGAINST CHLAMYDIAL INFECTION
    Publication number: 20140056967
    Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
    Type: Application
    Filed: August 13, 2013
    Publication date: February 27, 2014
    Applicants: GlaxoSmithKline Biologicals S.A., Corixa Corporation
    Inventors: Brenda Barth, India Ajay, Mark Alderson, Jean-Francois L. Maisonneuve, Yves Lobert, Florence Bernadette Nozay, Martine Marchand, Pascal Mettens, Yasir A. Skeiky, Peter Probst
  • Vaccines against chlamydial infection
    Patent number: 8541007
    Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: September 24, 2013
    Assignees: GlaxoSmithKline Biologicals S.A., Corixa Corporation
    Inventors: Mark Alderson, Ajay Bhatia, Yves Lobet, Brenda Maisonneuve, Jean-Francois L Maisonneuve, Martine Marchand, Pascal Mettens, Florence Bernadette Nozay, Peter Probst, Samira H Skeiky
  • MODIFIED TUBERCULOSIS ANTIGENS
    Publication number: 20120294882
    Abstract: Modified Rv3616c proteins and their use as medicaments, particularly for the prevention of reactivation of tuberculosis.
    Type: Application
    Filed: January 27, 2011
    Publication date: November 22, 2012
    Inventors: Normand Blais, James Brown, Anne-Marie Gelinas, Pascal Mettens, Dennis Murphy
  • NOVEL COMPOSITIONS AND METHODS
    Publication number: 20110223200
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv1753c protein sequence; (ii) a variant of an Rv1753c protein sequence; or (iii) an immunogenic fragment of an Rv1753c protein sequence.
    Type: Application
    Filed: July 24, 2009
    Publication date: September 15, 2011
    Inventors: James Brown, Pascal Mettens, Dennis Murphy
  • TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF
    Publication number: 20110206712
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis.
    Type: Application
    Filed: July 24, 2009
    Publication date: August 25, 2011
    Inventors: James Brown, Pascal Mettens, Dennis Murphy
  • NOVEL COMPOSITIONS AND METHODS
    Publication number: 20110117119
    Abstract: The present invention is directed to a polypeptide which comprises: (i) an Rv3616c protein sequence; (ii) a variant of an Rv3616c protein sequence; or (iii) an immunogenic fragment of an Rv3616c protein sequence for use in the treatment or prevention of latent TB. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of latent tuberculosis.
    Type: Application
    Filed: July 24, 2009
    Publication date: May 19, 2011
    Inventors: Pascal Mettens, James Brown, Dennis Murphy
  • Vaccines Against Chlamydial Infection
    Publication number: 20100172927
    Abstract: Methods and compositions for the treatment or prevention of ocular Chlamydia trachomatis infection. Compositions comprise one or more Chlamydia trachomatis proteins, immunogenic fragments thereof or polynucleotides encoding such proteins or fragments.
    Type: Application
    Filed: October 3, 2007
    Publication date: July 8, 2010
    Inventors: Mark Alderson, Rhea Coler, Yves Lobet, Jean-Francois L. Maisonneuve, Pascal Mettens, Peter Probst, Steven Reed
  • Dendritic-like cell/tumor cell hybrids and hybridomas for inducing an anti-tumor response
    Publication number: 20090081127
    Abstract: The present invention relates to a method of producing a plurality of dendritic cell/tumor cell hybrids which induce an anti-tumor response when applied to a patient. The present invention further relates to a method of producing a dendritic cell/tumor cell hybridoma which induces an anti-tumor response when applied to a patient.
    Type: Application
    Filed: May 27, 2008
    Publication date: March 26, 2009
    Inventors: Muriel Moser, Leo Oberdan, Laurence Lespagnard, Jacques Urbain, Catherine Bruyns, Catherine Gerard, Michel Goldman, Thierry Velu, Fabienne Willems, Nicole Tasiaux, Jason Perret, Anne-Marie Verheyden, Pascal Mettens, Kris Thielemans
  • VACCINES AGAINST CHLAMYDIAL INFECTION
    Publication number: 20090022755
    Abstract: The present invention relates to compositions comprising proteins or polynucleotides of Chlamydia sp., in particular combinations of proteins or polynucleotides encoding them, and methods for the use of the proteins or polynucleotides in the treatment, prevention and diagnosis of Chlamydia infection.
    Type: Application
    Filed: March 24, 2006
    Publication date: January 22, 2009
    Applicants: GLAXOSMITHKLINE BIOLOGICALS SA, CORIXA CORPORATION
    Inventors: Brenda Barth, Ajay Bhatia, Mark Alderson, Jean-Francois L. Maisonneuve, Yves Lobet, Florence Bernadette Nozay, Martine Marchand, Pascal Mettens, Yasir A. Skeiky, Peter Probst
  • Vaccine comprising il-12 or il-23 for treatment of autoimmune diseases
    Publication number: 20070048261
    Abstract: The present invention provides improved vaccines and immunogenic compositions comprising IL-12 or IL-23, and processes for the preparation of such vaccines and immunogenic compositions.
    Type: Application
    Filed: December 14, 2004
    Publication date: March 1, 2007
    Applicant: GlaxoSmithKline Biologicals S.A.
    Inventors: Pascal Mettens, Catherine Uyttenhove, Jacques Van Snick
  • Novel composition
    Publication number: 20050287137
    Abstract: The present invention relates to novel therapies and treatments of atherosclerotic diseases. Accordingly there is provided, methods of treating or preventing atherosclerosis by passive vaccination through administration to a patient of a fully human antibody that is capable of binding to the specific fragments of ApoCIII. Specific human monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the antibodies of the present invention in medicine.
    Type: Application
    Filed: June 27, 2005
    Publication date: December 29, 2005
    Inventors: Patrick Dhaese, Pascal Mettens, Rene Meykens, Philippe Monteyne, Torbjorn Schiott, Leif Strandberg
  • Novel composition
    Publication number: 20040185044
    Abstract: The present invention relates to novel therapies and treatments of atherosclerotic diseases. Accordingly there is provided, methods of treating or preventing atherosclerosis by passive vaccination through administration to a patient of a fully human antibody that is capable of binding to the specific fragments of ApoCIII. Specific human monoclonal antibodies and their use in therapy of atherosclerosis is provided. There is further provided the use of the antibodies of the present invention in medicine.
    Type: Application
    Filed: July 15, 2003
    Publication date: September 23, 2004
    Inventors: Patrick Dhaese, Pascal Mettens, Rene Meykens, Philippe Monteyne, Torbjorn Schiott, Leif Strandberg